Latest Competition News

Prescient Therapeutics has opened a Share Purchase Plan to raise up to $7 million, offering shareholders discounted shares to fund the Phase 2 development of its targeted cancer therapy PTX-100.

Helia Group reveals ING Bank Australia will not renew its Lenders Mortgage Insurance contract beyond June 2026, prompting a strategic business review amid evolving market dynamics.

Enero Group has appointed Ian Ball as its new CEO, marking a pivotal leadership transition following significant operational achievements and a strategic refocus.

Santana Minerals has released an updated Pre-Feasibility Study for its Bendigo-Ophir Gold Project, showcasing higher gold grades, reduced capital costs, and robust financial returns that position the project as a compelling new gold mine in New Zealand.

Pancontinental Energy’s latest technical update reveals promising hydrocarbon potential in the PEL 87 offshore Namibia project, supported by advanced seismic and basin modelling studies. These findings set the stage for revised resource estimates later this month.

EMVision Medical Devices has activated five of six pivotal trial sites for its emu™ bedside brain scanner, advancing towards FDA clearance while launching a parallel innovation study in Australia.

The Reject Shop Limited shares have been suspended from ASX trading following Federal Court approval of Dollarama Inc.'s acquisition scheme. This marks a pivotal step in the retailer's transition under new ownership.

Findi Limited will have its trading suspension lifted on 2 July 2025 following the lodgement of its 2025 annual report, reopening its shares to market activity.

Tlou Energy has admitted to a late filing of a key director interest notice for its former Managing Director, prompting an ASX inquiry into its compliance processes. The company vows to tighten internal controls following the breach.

The Federal Court has approved Dollarama’s acquisition of The Reject Shop, triggering a suspension of TRS shares on the ASX and setting the stage for upcoming cash payments to shareholders.

Echo IQ has initiated a pivotal clinical validation study with the Mayo Clinic Platform to test its EchoSolv HF software, marking the final step before its planned FDA submission in late 2025.

archTIS Limited has secured A$7.5 million through a discounted share placement to fund expansion in the U.S. defence sector, deepen strategic partnerships, and accelerate product innovation focused on secure data collaboration.